Newsfiscal.ai
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
· Published
Article summary
BriaCell Therapeutics Corp. announced the presentation of a poster at the ESMO 2026 Congress detailing a circulating immune biomarker linked to clinical outcomes in metastatic breast cancer patients.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…